Kornimate/medical-research-clean huggingface dataset:
analysis of suicide dynamics in link to the covid-19 pandemic

Conditions: COVID-19

Summary: covid is a virus that first appeared in china in 2019 and was quickly described as a pandemic virus by its globalized nature. the unprecedented occurrence of the virus has led to several health and restrictive government measures. the covid-19 pandemic and health measures have been able to contribute to the deterioration of the mental health of citizens as it has already been observed during the former pandemic context (sars covid in 2003 in china or the spanish flu). among the consequences of a negative impact on mental health, investigators assume that there is an increase in transitions to the completed suicidal act. however, current studies and observations tend to note that there has been no major change in the dynamics of successful suicides during the covid period. however, there are biases in the studies conducted: some suicide deaths may have been hidden and not reported as such, due to several factors. for example, the measure of the evolution of suicide attempts that was most often made by the measure of the evolution of the number of hospitalizations for this reason can be a source ofestimate whether people who did this gesture were not hospitalized after a visit to the emergency room or if they gave up attending because of the pandemic. moreover, suicide deaths are more difficult to report as such when they occur at home than after hospitalization. it is therefore interesting to study the dynamics of suicide during this health crisis retrospectively based on data from the strasbourg institute of forensic medicine containing the census of the alsace region, which was hit hard by the pandemic.


Eligibility criteria:
inclusion criteria: * adult patient * died between 01/01/2018 and 12/31/2021 * absence of opposition from the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes. exclusion criteria: * presence of opposition by the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes.

Keywords: covid-19 suicide
observation and evaluation of short-term curative effect of local advanced cervical cancer treated with particle radiotherapy versus neoadjuvant chemotherapy

Conditions: Uterine Cervical Neoplasms; Locally Advanced Cervical Cancer

Summary: locally advanced cervical cancer (lacc) refers to the clinically cervical visible lesion with a diameter of \> 4 cm, which has been considered as a high risk of early cervical cancer for a long time. because of local bulk lesion of lacc, the risk of radical hysterectomy is pretty high and the radical effect commonly does not meet the satisfactory. therefore, 1-3 course of neoadjuvant chemotherapy (nact) were carried out before operation. however, nearly 20% of patients are not sensitive to nact. therefore nact did not bring any benefits to radical surgery even to some extent delayed the treatment. traditional radiotherapy is also commonly used in the treatment of lacc, however ovarian function would be permanently destroyed especially for young patients, additionally radioactive complications to adjacent organs of cervical such as vagina, bladder and rectal also commonly happened, moreover sexual dysfunction after radiotherapy significantly affect the life quality of young patients. particle radiotherapy developed recently, has the advantages of short course of treatment and mild side effects, due to its special working mechanism, bragg effect. so the amount of radiation in the tumor tissue is very extremely high, and in the adjacent tissue is quiet low, therefore the organs at risk were protected by avoiding unnecessary damage. based on these, we proposed the application of particle radiotherapy in lacc pre-operation, and comprehensively evaluated recent curative effect, complications and long-term follow-up between particle radiotherapy and nact. furthermore, the clinical significance and long-term application prospects about particle therapy were objectively assessed.


Eligibility criteria:
inclusion criteria: 1. pathological diagnosis: squamous carcinoma, adenocarcinoma, adenosquamous carcinoma 2. the pathological staging: ib2，iia2 exclusion criteria: underwent surgery or radiation and chemotherapy

Keywords: locally advanced cervical cancer particle radiotherapy neoadjuvant chemotherapy
sedative effects in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the objective of this study is to determine the effect of dexmedetomidine infusion on the apnea / hypopnea index (ahi) of individuals with previously documented obstructive sleep apnea. we hypothesize that dexmedetomidine infusion may reduce the ahi in patients with obstructive sleep apnea (osa).


Eligibility criteria:
inclusion criteria: * all individuals who have previously undergone diagnostic polysomnography in the sleep lab which documented significant osa, and who have not undergone any changes that are likely to alter the severity of their condition since the time of their diagnostic sleep study (loss of weight; surgical therapy for osa; removal of tonsils; discontinuation of medications likely to affect arousal or respiratory function, etc.) are eligible to participate. subjects will be identified as they complete outpatient sleep studies or from records of previous sleep studies performed in the duke sleep laboratory. after obtaining informed consent, subjects will be screened by history and physical examination, 12-lead electrocardiogram, and comprehensive metabolic profile. exclusion criteria: * exclusion criteria will include a history of illicit drug or alcohol dependence, impaired hepatic (aspartate aminotransferase or alanine aminotransferase \> 2x upper limit of normal range) or renal function (receiving dialysis or serum creatinine \> 1.5 mg/dl), high-grade (\> 1st degree) heart block, or known allergy to dexmedetomidine.
pediatric aggression and violence

Conditions: Pediatric Aggression and Violence

Summary: violence and aggression on pediatric psychiatry units has led to staff and patient injuries and even deaths around the country. in an effort to improve safety, the investigators have developed a method (with the brief rating of child and adolescent aggression) of identifying children and adolescents at a higher risk for aggression and violence on the units. in order to improve this prediction, the investigators plan to study salivary hormones in low risk children and high risk children. the salivary hormones to be studied include cortisol, testosterone, and dehydroepiandrosterone sulfate (dheas). the investigators expect to improve the investigators current ability to predict the severity and type of pediatric aggression and violence on the inpatient units by combining information from the brief rating of child and adolescent aggression (bracha), the predatory-affective aggression scale (vitiello et al., 1990), and salivary hormones.


Eligibility criteria:
inclusion criteria: 1. prepubescent males (per parent report), african american or caucasian, between 7 and 9 years old 2. ability of the subject to provide assent 3. ability of the guardian to give parental permission 4. completion of the bracha questionnaire 5. completion of the predatory-affective aggression scale (paas) exclusion criteria: 1. viral or bacterial infection or treatment with antibiotics within two weeks of screening 2. recent surgery (within 8 weeks of screening) 3. bleeding gums (within 8 weeks of screening) 4. currently detained in a juvenile detention 5. currently taking medications such as antipsychotic medications (besides aripiprazole), steroids and beta adrenergic agonists that affect hormones 6. if it is the investigator's clinical judgment that the subject should be excluded if it is in the subject's best interest or due to any other factor that may interfere with study results
assisted animal therapy: reanimal

Conditions: Anxiety; Mood Disorders; Post Traumatic Stress Disorder

Summary: assisted animal therapy (aat) is getting more and more used worldwide, in such areas as gerontology, psychiatry, or oncology. it is a complementary therapy, and benefits for patients are various, including decrease of anxiety. in icu, some case reports exist, but no study has ever been made in order to prove its benefits, not even its feasibility. in reanimal, the investigator aims to compare a group of patients receiving assisted animal therapy, versus a group of patients not receiving it. primary objective will be the evolution of anxiety scores between the 2 groups of patients. secondary objectives will be the comparison of mood scores, post traumatic stress syndrome scores, pain scores, and physiologic parameters such as blood pressure, cardiac frequency. the investigating team will also compare multi drug resistant bacteria incidence between the 2 groups. in the assisted animal therapy group, patients will also be asked to answer a satisfaction questionnaire.


Eligibility criteria:
inclusion criteria: * patients hospitalized in surgical icu, not in acute stage of their icu stay * adult patient * able to receive information and to give consent, * with national social insurance exclusion criteria: * afraid of animal, dog phobia * allergic to dog * immunodepression (neutrophils \<0.5 g/l), induced by treatment (chemotherapy, immunosuppressing treatment with high doses, corticotherapy for more than 2 weeks) or induced by disease (malignant blood disease, aids, transplantation, or splenectomy) * sepsis ongoing * patient known for having multidrug resistant bacteria * wounds, or large bandages that could not correctly be covered, including external fixer * central venous catheter, arterial catheter * tracheostomy * agitation, aggressiveness * pregnant women * patient deprived of freedom by juridical or administrative decision * patient under legal protection measure * patient receiving enforced psychiatric treatment * patient admitted in a sanitary or social department.

Keywords: animal assisted therapy intensive care unit anxiety
open-label study of exemestane with or without celecoxib in postmenopausal women with abc having progressed on tamoxifen

Conditions: Breast Neoplasms

Summary: this is an open-label, multicenter, randomized (1:1 randomization ratio) study of either exemestane or exemestane plus celecoxib in postmenopausal women with abc having progressed on tamoxifen.


Eligibility criteria:
inclusion criteria: * postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on tamoxifen. * advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following \> 8 weeks of treatment with tamoxifen for advanced disease; or progressed during adjuvant tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with tamoxifen. * at least one measurable lesion exclusion criteria: * more than one previous chemotherapy and/or more than one hormonotherapy for advanced disease. * previous hormonotherapy for advanced disease other than tamoxifen. * myocardial infarction within previous 6 mo
the effect of bevacizumab on corneal neovascularization

Conditions: Corneal Neovascularization

Summary: eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. all patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. patients were monitored by ophthalmic exam and anterior segment photography.

to evaluate the effect of repeated subconjunctival bevacizumab (avastin®, roche, rio de janeiro, brazil) on inflammatory corneal neovascularization. eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. all patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. patients were monitored by ophthalmic exam and anterior segment photography.

Eligibility criteria:
inclusion criteria: * corneal neovascularization * stable lesion exclusion criteria: * diabetes * autoimmune diseases

Keywords: bevacizumab cornea neovascularization
effectiveness of group cbt in children with mixed psychiatric disorders

Conditions: Child Behavior Problem

Summary: this study aims to examine the immediate and longer-term effectiveness of a group cognitive behavioral therapy intervention (gcbt) in reducing internalizing and externalizing symptoms in children treated for mixed psychiatric disorders in naturalistic clinical settings. further, the effectiveness of gcbt is compared to a treatment-as-usual condition (tau). within this study, it is hypothesized that children with mixed psychiatric disorders will exhibit improvements in parent-rated internalizing problem behavior and parent- and teacher-rated externalizing problem behavior following gcbt.


Eligibility criteria:
inclusion criteria: * helsinki university hospital child psychiatric outpatient clinic patients with symptoms of anxiety or depression, deficiencies in emotional and behavioral skills impairing functioning, and sufficient social and cognitive skills to participate in group work. exclusion criteria: * helsinki university hospital child psychiatric outpatient clinic patients with excessive physical aggression, excessive physical restlessness to enable skill training, or whose severity of psychiatric symptoms required individual psychotherapy (e.g., acute suicidality or psychosis).

Keywords: children group cognitive behavioral therapy cognitive behavioral therapy internalizing symptoms externalizing symptoms
comparison of cardiac computed tomographic angiography (cta) to tc-99m single photon emission computed tomography (spect)

Conditions: Coronary Artery Disease

Summary: cardiovascular disease and ischemic heart disease is the #1 killer in canada. currently, cardiac invasive catheterization angiography (cica) is the gold standard for the assessment of the arteries in the heart. however, cardiac catheterization has risks which prohibit its use in all patients. these risks include: death, heart attack, stroke and bleeding. cardiac computed tomography angiography (cta) is a new non-invasive technology which may enable the evaluation of patients' coronary anatomy without exposing patients to the risks of invasive cardiac catheterization. the purpose of this project is to compare ct angiography (cta) to tc-99m single photon emission computed tomography (tc-99m spect) we will enroll patients who are waiting for a cica or who have been referred for a tc-99m spect or cta scans at the university of ottawa heart institute. consenting patients who are waiting for a cica will have both a cta and a tc-99m spect scan. consenting patients referred for a cta or tc-99m spect will have both the cta and tc-99m spect in a random order but not cica (unless ordered by your physician).


Eligibility criteria:
inclusion criteria: * patients referred for tc-99m spect or cta; or * patients referred for cica without preceding (\< 12 months) mpi or cta exclusion criteria: * previous revascularization (pci or cabg) * age \< 18 years or lack of consent * renal insufficiency (gfr \< 60 ml/min) * allergy or contraindication to contrast agent or dipyridamole * refractory angina requiring urgent/emergent coronary angiography * contraindication to radiation exposure (e.g. pregnancy) * uncontrolled hr * atrial fibrillation, frequent atrial or ventricular ectopy (\> 1/minute) * unable to perform 10 second breath-hold

Keywords: cardiac invasive catheterization angiography single photon emission computed tomography computed tomography angiography
a pilot study of high-dose, intravenous ascorbic acid (vitamin c) to treat hepatitis c

Conditions: Hepatitis C

Summary: the purpose of this pilot study is to learn whether high doses of ascorbic acid (vitamin c), given intravenously to patients with chronic hepatitis due to infection with the genotype 1 version of the hepatitis c virus, are safe, well-tolerated and able to reduce the amount of virus circulating in the patients' blood.

hepatitis c virus (hcv) chronically infects 1% to 3% of the world's population, including about 3.9 million infected patients in the united states, with an estimated 36,000 new cases in the us each year. 70-85% of infected individuals develop a chronic infection complicated by chronic liver disease during the next 20 to 30 years, which is the tenth leading cause of death in the us. hcv is implicated in the development of hepato-cellular carcinoma. chronic hcv hepatitis is the most frequent reason for liver transplantation. hcv genotype 1 is the most common genetic variant of hcv causing hcv hepatitis in the us. it responds less well to conventional anti-hcv treatment than the other hcv genotypes, so that 60% of genotype 1 patients fail conventional therapy due to the virus's resistance to treatment and/or due to toxic side effects of the therapy. extracellular levels of ascorbic acid (vitamin c) attainable only by high-dose, intravenous administration, are reported to have in vitro and in vivo anti-cancer and anti-viral effects in humans and animals. ascorbic acid briefly generates extracellular hydrogen peroxide, an oxidative stress specifically toxic to cancer cells and cells infected with viruses, including hcv, but not to normal cells. high-dose, intravenous ascorbic acid has been given to large numbers of patients, particularly cancer patients, with anecdotal reports of good safety and occasional benefit. given the foregoing, the investigators propose that there is sufficient rationale for a careful pilot study of the safety and anti-viral efficacy of infused ascorbic acid in hcv genotype 1 hepatitis.

Eligibility criteria:
inclusion criteria: * hepatitis c, genotype 1 * failed treatment with interferon-alpha and ribavirin * abstain from alcohol consumption for the duration of the study exclusion criteria: * cirrhosis * decompensated liver disease * glucose6phosphate dehydrogenase deficiency * ast or alt more than 5 times upper limit of normal * platelets less than 125,000 * diabetes mellitus * alcohol and/or drug abuse within 1 year of screening

Keywords: genotype 1
phase i dose escalation safety study of retinostat in advanced age-related macular degeneration (amd)

Conditions: Age Related Macular Degeneration

Summary: the purpose of this first in man study is to examine the safety of an experimental gene transfer agent, retinostat, designed to treat neovascular age-related macular degeneration.

there are two parts to the study. a dose-escalation phase looking at three doses of retinostat starting with the lowest dose, three patients will be recruited at each dose level. the escalation phase will be followed by a dose confirmation phase where the highest dose that is safe and well tolerated will be examined in 9 patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of amd with active cnv that shows evidence of leakage. * bcva less than or equal to 20/200 in the study eye for dose escalation phase. * bcva less than or equal to 20/80 in the study eye for maximum tolerated dose phase. exclusion criteria: * significant ocular abnormalities that prevent retinal assessment. * treatment with steroids within three months of screening. * treatment with anti-vegf therapy to either eye within one month of screening. * clinically significant intercurrent illnesses, laboratory, ecg or chest xray abnormalities.

Keywords: age related macular degeneration
effects of insomnia treatment on metabolism in patients with depression

Conditions: Insomnia Chronic; Insomnia; Insomnia, Primary; Depression; Depressive Symptoms

Summary: this project will examine changes in metabolism and depressive symptoms after receiving cbt-i in 30 subjects with insomnia disorder and mdd.


Eligibility criteria:
inclusion criteria: * insomnia severity index \> 14 * meet diagnostic criteria for insomnia * meet diagnostic criteria for major depressive disorder * either currently taking an ssri/snri or no antidepressant exclusion criteria: * bmi \> 30 * those with unstable medical conditions defined by change in diagnosis or medication in past 2 months * those with clinically significant comorbid psychiatric conditions (e.g., bipolar disorder) * those with known untreated sleep apnea or other clinically significant sleep disorder other than insomnia * those currently taking medications that affect sleep or metabolism (e.g., stimulants, thyroid meds)

Keywords: metabolism metabolomics
evaluation of longterm outcome of new york heart association class iii heart failure patients receiving telemonitoring using a pulmonary artery pressure sensor system (cardiomems)

Conditions: Chronic Heart Failure

Summary: invasive hemodynamic monitoring in advanced heart failure patients is a relative new option. in order to investigate the impact of remote telemonitoring of pulmonary artery pressures on mortality and morbidity in a routine clinical setting in germany, the investigators initiated this multicenbtric registry.

all patients who receive invasive hemodynamic monitoring using a pulmonary artery pressure sensor (cardiomems device) are offered participation in the registry. routine heart-failure parameters, lab values, medication and qol as obtained on the regular outpatients visits in the department are entered into a registry-specific database. the investigators plan to asses the impact of telemonitoring on mortality, morbidity and qol as well as on guideline-recommended heart failure medication. in addition, it is planned to quantify the input in person time for telemonitoring.

Eligibility criteria:
inclusion criteria: * implantation of cardiomems successful * telemonitoring according to the sop of the frankfurt heart failure center (goethe university) exclusion criteria: * unwillingness to participate in the registry